ANCA相关性系统性血管炎的治疗进展被引量：1

ANCA-ASSOCIATED SYSTEMIC VASCULITIS:TREATMENT

下载PDF

导出

摘要 ANCA相关性系统性血管炎是容易引起肾脏和肺脏等多器官严重损害的一组疾病,远期预后较差,及时采取有针对性的、合理的治疗是降低并发症,减轻肾脏损伤,改善预后的关键,也是一直以来相关专业的临床医师所期待解决的问题。本文介绍了近年来ANCA相关性系统性血管炎的治疗进展,特别是15-脱氧精胍菌素、TNF阻滞药、利妥昔单抗等针对不同靶点的治疗在临床的应用情况,期望为临床医师提供一些帮助。 The antineutrophil cytoplasmic antibody （ANCA） -associated systemic vasculitis （AASV） with its appalling prognosis is drawing international attention and effort in exploring its patho- genesis as well as satisfying treatment. The standard therapy - combination of cortieosteroids and cyclophosphamide has dramatically advanced patient survival,however,the associated risk of relapse and severe, even life-threatening, treatment-related morbidity has caused wide concern, which is encouraging investigation of new approaches using less toxic immunosuppressant or orienting different pathogenic targets. This article provides an overview on the alternative therapies showing potential capacity in minimizing toxicity and improving efficacy about their mechanism and effect, in order to enrich and op-timise AASV clinical treatment approach.

作者刘琳龚莉

机构地区天津南开大学临床医学院内蒙古自治区医院肾内科

出处《内蒙古医学院学报》 2008年第6期476-480,共5页 Acta Academiae Medicinae Neimongol

基金内蒙古自治区教育厅自然科学研究(重点)(NJZZ07087)

关键词抗中性粒细胞胞质抗体血管炎治疗 antineutrophil cytoplasmic antibody vasculitis treatment

分类号 R543 [医药卫生—心血管疾病] R453 [医药卫生—治疗学]

引文网络
相关文献

参考文献26

1Fauci AS, Wolff SM. Wegner' s granulomatosis : studies in eighteen patients and a review of the literature [ J ]. Medicine,1973 ;52(6) :535 -561
2De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody - associated vascuhtis [ J ]. Arthritis Rheum,2005 ; 52 ( 8 ) :2237 - 2242
3Reinhold - Keller E, Fink CO, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegner' s granulomatosis under maintenance of remission with low - dose methotrexate [ J ]. Arthritis Rheum,2002 ;47 ( 3 ) :326 - 332
4Jayne D, Rasmussen N, Andrassy K. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies [ J ]. N Engl J Med, 2003 ;349( 1 ) :3 -4
5Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement [ J ]. Nephrol Dial Transplant ,2008 ;23(4) : 1307 - 1312
6Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti- neutrophil cytoplasmic antibody -associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide [ J ]. Ann Rheum Dis,2007 ;66(6) :798 - 802
7Koukoulaki M,Jayne DR. Mycophenolate mofetil in anti - neutrophil cytoplasm antibodies - associated systemic vasculitis [ J ]. Nephron Clin Pract, 2006 ; 102 ( 3 - 4 ) : 100 - 107
8Joy MS, Hogan SL, Jennette JC. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis [ J ]. Nephrol Dial Transplant, 2005 ; 20 (12) : 2725 - 2732
9Haubitz M,de Groot K. Tolerance of mycophenolate mofetil in end - stage renal disease patients with ANCA - associated vasculitis [ J ]. Clin Nephrol,2002 ;57 (6) :421 - 424
10Langford CA, Talar - Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegner' s granulomatosis [ J ]. Arthritis Rheum, 2004; 51(2) :278 -283